IL122649A - (1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same - Google Patents

(1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same

Info

Publication number
IL122649A
IL122649A IL12264996A IL12264996A IL122649A IL 122649 A IL122649 A IL 122649A IL 12264996 A IL12264996 A IL 12264996A IL 12264996 A IL12264996 A IL 12264996A IL 122649 A IL122649 A IL 122649A
Authority
IL
Israel
Prior art keywords
phenylpiperidin
medicaments
hydroxyphenyl
hydroxy
preparation
Prior art date
Application number
IL12264996A
Other languages
English (en)
Other versions
IL122649A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL122649A0 publication Critical patent/IL122649A0/xx
Publication of IL122649A publication Critical patent/IL122649A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL12264996A 1995-08-11 1996-06-20 (1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same IL122649A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US223895P 1995-08-11 1995-08-11
PCT/IB1996/000592 WO1997007098A1 (en) 1995-08-11 1996-06-20 (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate

Publications (2)

Publication Number Publication Date
IL122649A0 IL122649A0 (en) 1998-08-16
IL122649A true IL122649A (en) 2001-08-26

Family

ID=21699847

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12264996A IL122649A (en) 1995-08-11 1996-06-20 (1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same

Country Status (41)

Country Link
US (1) US6008233A (hu)
EP (1) EP0843661B1 (hu)
JP (1) JP3099072B2 (hu)
KR (1) KR100291882B1 (hu)
CN (2) CN1198739A (hu)
AP (1) AP755A (hu)
AR (1) AR004676A1 (hu)
AT (1) ATE215072T1 (hu)
AU (1) AU710984B2 (hu)
BG (1) BG63678B1 (hu)
BR (1) BR9610766A (hu)
CA (1) CA2228752C (hu)
CO (1) CO4750830A1 (hu)
CZ (1) CZ296236B6 (hu)
DE (1) DE69620191T2 (hu)
DK (1) DK0843661T3 (hu)
DZ (1) DZ2083A1 (hu)
ES (1) ES2170857T3 (hu)
GT (1) GT199600051A (hu)
HR (1) HRP960372B1 (hu)
HU (1) HUP9802862A3 (hu)
IL (1) IL122649A (hu)
IS (1) IS1945B (hu)
MA (1) MA23957A1 (hu)
NO (1) NO310458B1 (hu)
NZ (1) NZ309134A (hu)
OA (1) OA10664A (hu)
PE (1) PE4898A1 (hu)
PL (1) PL185603B1 (hu)
PT (1) PT843661E (hu)
RO (1) RO120134B1 (hu)
RS (1) RS49521B (hu)
RU (1) RU2140910C1 (hu)
SA (1) SA96170171B1 (hu)
SK (1) SK284209B6 (hu)
TN (1) TNSN96104A1 (hu)
TR (1) TR199800208T1 (hu)
TW (1) TW495502B (hu)
UA (1) UA59341C2 (hu)
WO (1) WO1997007098A1 (hu)
ZA (1) ZA966760B (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9701282A (es) * 1994-08-18 1997-05-31 Pfizer Fenoles neuroprotectores.
BR9610766A (pt) * 1995-08-11 1999-07-13 Pfizer Triihdrato de metanossulfonato de (1s,2s)-1-(4-hidróxi-fenil)-2-(4-hidróxi-4-fenilpiperidin-1-il)-1-propanol
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
EP1182193A4 (en) * 1999-04-09 2002-09-11 Mochida Pharm Co Ltd REMEDIES FOR NEUROGENIC PAIN
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
YU27801A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera
YU27701A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)1-propanola
MXPA03001472A (es) 2000-08-16 2003-06-06 Upjohn Co Compuestos para el tratamiento de trastornos adictivos.
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
BRPI0213393B8 (pt) * 2001-10-19 2021-05-25 Fujifilm Toyama Chemical Co Ltd derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
CA2628074C (en) 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
KR20100017255A (ko) 2007-04-24 2010-02-16 시오노기 앤드 컴파니, 리미티드 환식기로 치환된 아미노다이하이드로싸이아진 유도체
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
EP2634186A4 (en) 2010-10-29 2014-03-26 Shionogi & Co naphthyridine
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
EP2703399A4 (en) 2011-04-26 2014-10-15 Shionogi & Co OXAZINE DERIVATIVE AND BACE-1 HEMMER THEREOF
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
JP6612331B2 (ja) 2014-09-15 2019-11-27 リューゲン ホールディングス （ケイマン） リミテッド Ｎｒ２ｂ ｎｍｄａ受容体アンタゴニストとしてのピロロピリミジン誘導体
WO2016049048A1 (en) * 2014-09-22 2016-03-31 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
WO2016126869A1 (en) 2015-02-04 2016-08-11 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
ES2784398T3 (es) 2015-06-01 2020-09-24 Rugen Holdings Cayman Ltd Compuestos heterocíclicos de 3,3-difluoropiperidina carbamato como antagonistas del receptor de NMDA NR2B
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
SK232890A3 (en) * 1989-05-17 1998-11-04 Pfizer 2-piperidino and 2-pyrrolidino-1-alkanols derivatives and preparation method thereof
MX9701282A (es) * 1994-08-18 1997-05-31 Pfizer Fenoles neuroprotectores.
BR9610766A (pt) * 1995-08-11 1999-07-13 Pfizer Triihdrato de metanossulfonato de (1s,2s)-1-(4-hidróxi-fenil)-2-(4-hidróxi-4-fenilpiperidin-1-il)-1-propanol

Also Published As

Publication number Publication date
YU46196A (sh) 1999-07-28
PL185603B1 (pl) 2003-06-30
NO310458B1 (no) 2001-07-09
EP0843661A1 (en) 1998-05-27
ZA966760B (en) 1998-02-09
MA23957A1 (fr) 1997-04-01
GT199600051A (es) 1997-12-26
CZ39098A3 (cs) 1999-02-17
DE69620191D1 (de) 2002-05-02
IL122649A0 (en) 1998-08-16
PE4898A1 (es) 1998-03-16
CO4750830A1 (es) 1999-03-31
CA2228752C (en) 2002-12-10
TNSN96104A1 (fr) 2005-03-15
AR004676A1 (es) 1999-03-10
HUP9802862A3 (en) 1999-05-28
WO1997007098A1 (en) 1997-02-27
SA96170171B1 (ar) 2006-05-20
SK284209B6 (en) 2004-11-03
PT843661E (pt) 2002-07-31
RU2140910C1 (ru) 1999-11-10
HUP9802862A2 (hu) 1999-04-28
NZ309134A (en) 1999-09-29
SK16698A3 (en) 1999-06-11
NO980574L (no) 1998-02-10
CZ296236B6 (cs) 2006-02-15
UA59341C2 (uk) 2003-09-15
BG63678B1 (bg) 2002-09-30
CN1198739A (zh) 1998-11-11
ATE215072T1 (de) 2002-04-15
IS4643A (is) 1997-12-30
IS1945B (is) 2004-08-13
HRP960372B1 (en) 2003-04-30
TR199800208T1 (hu) 1998-05-21
RS49521B (sr) 2006-10-27
JPH10510552A (ja) 1998-10-13
EP0843661B1 (en) 2002-03-27
RO120134B1 (ro) 2005-09-30
ES2170857T3 (es) 2002-08-16
PL325050A1 (en) 1998-07-06
AP9600856A0 (en) 1996-10-31
AU5908496A (en) 1997-03-12
KR100291882B1 (ko) 2001-10-26
US6008233A (en) 1999-12-28
AU710984B2 (en) 1999-10-07
BG102289A (en) 1998-09-30
CN1615861A (zh) 2005-05-18
OA10664A (en) 2000-11-06
BR9610766A (pt) 1999-07-13
MX9801149A (es) 1998-05-31
DK0843661T3 (da) 2002-07-22
KR19990036321A (ko) 1999-05-25
NO980574D0 (no) 1998-02-10
JP3099072B2 (ja) 2000-10-16
DE69620191T2 (de) 2002-07-18
HRP960372A2 (en) 1998-04-30
AP755A (en) 1999-08-02
TW495502B (en) 2002-07-21
CA2228752A1 (en) 1997-02-27
DZ2083A1 (fr) 2002-10-23

Similar Documents

Publication Publication Date Title
IL122649A (en) (1s, 2s) - 1- (4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate, its use in the preparation of medicaments and pharmaceutical compositions comprising same
GB9407386D0 (en) Pharmaceutical formulation
GB9402203D0 (en) Pharmaceutical formulation
IL112521A0 (en) Pharmaceutical formulation
EP0841936A4 (en) CONJUGATION-STABILIZED THERAPEUTIC AGENT COMPOSITIONS, ADDITIONAL FORMULATIONS AND DIAGNOSTICS
NZ305166A (en) 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
IL115039A (en) Spiroazabicyclic compounds, their preparation and pharmaceutical compositions containing them
HU0301171D0 (en) Antifungal active ingredients, pharmaceutical compositions containing the same and process for their preparation
HK1010484A1 (en) Pharmaceutical composition for use in treatment ofdiabetes.
GB2314022B (en) Blending medical composition with sustained medicament releasability and process for preparing the same
IL133784A (en) Dolastatin 15 derivatives, pharmaceutical compositions comprising them and their use in medicaments for treating cancer
SI0825178T1 (en) Phenyl-substituted alkenoylguanidides, process for their preparation, their use as drugs or in diagnostic agents and drugs containing them
IL123013A (en) Substituted imidazoles having biphenylsulfonyl substitution, and pharmaceutical compositions comprising them
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
EP1013269A4 (en) IMPROVEMENT OF A DRUG ADMINISTRATION SYSTEM
HUP9802132A3 (en) Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them
GB9405856D0 (en) Pharmaceutical formulation
HK1035719A1 (en) Azabicyclic compounds, pharmaceutical composition containing them and their medicinal use
GB9416599D0 (en) Pharmaceutical formulation
HUT77375A (hu) Enterokinetikus hatású benzamidszármazékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítására
IL117989A (en) N-(1-(3,5-bisfluoromethylbenzoyl)-2- benzyl-piperidin-4-YL)-4-oxo-4H-1- benzopyran-2 carboxamides their preparation and pharmaceutical compositions comprising them
EP0672052A1 (en) TACHYQUININ ANTAGONISTS, THEIR PRODUCTION AND THEIR USE IN PHARMACEUTICAL FORMULATIONS.
HUT76052A (en) Azole derivatives having adhesion-receptor antagonistic effect, process for their preparation and pharmaceutical compositions containing the same
IL164513A0 (en) Pyrazolopyrimidines, pharmaceutical compositions containing them, and their use in the preparation of medicaments
ZA961983B (en) Bicyclic compounds, preparation thereof and use in pharmaceutical compositions.

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees